Clik here to view.
Dealing deadly cancers a knockout punch
New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers. Reovirus, a non-pathogenic virus under development at...
View ArticleClik here to view.
CTRC Enrolls First Patients in Phase II Study; Living Virus Destroys Cancer...
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II...
View ArticleClik here to view.
CTRC ENROLLS FIRST PATIENTS IN PHASE II STUDY
SAN ANTONIO– The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a...
View ArticleClik here to view.
Oncolytics Biotech Inc. announces approval for UK clinical trial
CALGARY, AB, --- October 24, 2007 - Oncolytics Biotech Inc. (“Oncolyticsâ€) (TSX:ONC, NASDAQ:ONCY) announced that it has received a letter of approval from the U.K. Medicines and Healthcare...
View Article
